Valuation
- Market cap
- 151,608,000
- Revenue TTM
- $27,470,000
- Net income TTM
- $-26,600,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -96.83%
- Debt to equity
- 0.00
Trading
- Volume
- 60,700
- Avg volume
- 275,162
- Day's range
- $19.85 – $21.17
- Shares out
- 7,264,000
- Stochastic %K
- 75%
- Beta
- 2.62
- Analysts
- Strong Buy
- Price target
- $81.02
Company profile
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead au...
Show more
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 949 2680
- Website
- https://www.cuebiopharma.com
- Address
- 40 Guest Street, Boston, United States
Latest news
No headlines yet.
